Navelbine (Vinorelbine Tartrate)

Vinorelbine tartrate interferes with microtubule assembly by binding to tubulin, which blocks the formation of the mitotic spindle during cell division. This causes cancer cells to arrest in the M phase and undergo programmed cell death.

The specific dose of Navelbine is determined by the prescribing oncologist based on the patient’s cancer type, stage, body surface area, and overall health. Dosage regimens are individualized and should follow the prescriber’s instructions.

Navelbine is classified as pregnancy category D, indicating evidence of risk to the fetus. It should not be used during pregnancy unless the potential benefit justifies the risk. Breastfeeding is not recommended because the drug may pass into milk.

To request Navelbine, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Navelbine belongs to the Vinca alkaloid class, offering a distinct mechanism of microtubule inhibition compared with taxanes or platinum compounds. It is often used in combination with platinum agents and may provide comparable efficacy with a different side‑effect profile, particularly lower rates of alopecia.

Store Navelbine capsules at ambient temperature, below 25 °C, in the original packaging. Protect them from moisture, excessive heat and direct sunlight to maintain product stability.

Navelbine is taken orally as a capsule, usually on a scheduled day each treatment cycle. The capsule should be swallowed whole with water and not crushed or chewed, unless the prescriber provides an alternative administration instruction.

The most serious risks include severe neutropenia with fever (febrile neutropenia), pulmonary toxicity, peripheral neuropathy, and rare but life‑threatening allergic reactions. Patients should be monitored closely for signs of infection, breathing difficulties, or neurological changes.

Navelbine is contraindicated in patients with known hypersensitivity to vinorelbine or any Vinca alkaloid, in pregnant women unless absolutely necessary, and in individuals with severe bone‑marrow suppression or uncontrolled infections. Clinical judgment is required for patients with significant hepatic impairment.